Clinical Trial Update: Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update reporting safety, tolerability, and Abeta-specific antibody response for repeated intramuscular injections of adjuvanted CAD106 in mild Alz…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• CAD106

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED